Fred Poordad, University of Texas Health Science Center at San Antonio (IMAGE)

University of Texas Health Science Center at San Antonio

Fred Poordad, University of Texas Health Science Center at San Antonio

Caption

The US Food and Drug Administration has granted amended Breakthrough Therapy Designation for a promising drug combination to treat the sickest hepatitis C patients - those with advanced cirrhosis or who have had a liver transplant but the virus returned. The designation expedites drug development based on early results of the ALLY-1 clinical trial presented by Fred Poordad, M.D., from The University of Texas Health Science Center at San Antonio, at The International Liver CongressTM.

Credit

University of Texas Health Science Center at San Antonio

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.